Developer docs
API playgroundTry for free, no card

Search company profiles

Techcyte

Full company profile

uuid00007be

Namestring
Techcyte
Legal namestring
Techcyte, Inc.
Websiteurl
techcyte.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Techcyte is a digital pathology AI company founded in 2013 as a technology transfer from the University of Utah and headquartered in Orem, Utah. The company builds Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic pathology (AP) and clinical pathology (CP) workflows into a single workspace, addressing a market historically served by fragmented, single-purpose tools. Techcyte's core AI is built on proprietary deterministic convolutional neural networks trained to detect, classify, and count diagnostic objects (parasites, blood cells, bacteria, cervical cells, and pathology structures) on whole-slide microscopy images, validated with quantified accuracy metrics ranging from 95% to 98.9% in published studies. The platform is DICOM-native, supports all major WSI scanner formats, uses a microservices architecture on AWS, and integrates with LIS/EHR/PACS systems via HL7, FHIR, and DICOMweb standards.

The company operates across four verticals: human clinical pathology (parasitology, bacteriology, hematology, cervical cytology via SureView), veterinary diagnostics (embedded as the AI engine for Zoetis's Vetscan Imagyst platform), environmental testing (Sporecyte brand for mold and air quality), and food safety (Stericyte brand launched 2025). Revenue is generated through multi-year SaaS subscriptions, OEM/embedded licensing royalties (notably from Zoetis, where Techcyte AI powered 3M+ scans by 2024), professional services, and scanner distribution partnerships. Distribution combines direct enterprise sales, exclusive OEM partnerships (Zoetis for veterinary, BD for cervical cytology), and an ESP (Expert Solution Provider) international channel program. The company has raised approximately $36M+ across seed rounds, a 2021 Series E led by Zoetis, and a 2026 capital raise led by Van Tuyl Companies, with the veterinary segment already profitable and human/environmental segments targeting profitability by 2027.

Short descriptiontext

Techcyte builds Fusion, a cloud-based AI platform that unifies anatomic and clinical pathology workflows using deep learning on whole-slide images. It serves human clinical labs, veterinary clinics (via Zoetis), environmental testing labs, and food safety markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOrem, United States
HQ citystring
Orem
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology, clinical pathology AI, anatomic pathology, cytology diagnostics, laboratory diagnostics
Industry3 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Digital Pathology AI Software
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Subscription/SaaS
TypeSubscription Recurring
Description

Recurring subscription-based revenue from hosted SaaS access to Techcyte Fusion and related AI suites. Customers must sign subscription agreements to use the platform (per ESP portal terms). Includes ESP (Expert Solution Provider) international distribution tier.

techcyte.com
2Scanner distribution / hardware resale
TypeHardware Sales
Description

Techcyte acts as a trusted distributor of top whole-slide scanners (Hamamatsu, 3DHistech, Pramana, Motic, Grundium, MetaSystems), generating revenue from hardware sales or referral arrangements to support its platform deployments.

techcyte.com
3OEM/embedded licensing (Zoetis Vetscan Imagyst)
TypeLicensing Royalties
Description

Techcyte AI algorithms are embedded within Zoetis's Vetscan Imagyst platform — generating royalty/licensing revenue per test analyzed. Surpassed 3 million digital scans across Zoetis platform (2024) and over 2 million scans by 2023.

techcyte.com
4Professional services / implementation
TypeProfessional Services
Description

Implementation, training, onboarding, scanner consultation, and ongoing support services delivered alongside platform deployments; supported by in-app training and dedicated account management.

techcyte.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Custom enterprise subscription
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based; requires signed subscription agreement. International distribution via ESP (Expert Solution Provider) program.

techcyte.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Vetcyte
Description

AI-powered digital diagnostics platform for the veterinary industry, originally split out as a separate brand in 2016; powers VETSCAN IMAGYST in partnership with Zoetis.

techcyte.com
+4 more records
Core offering1 text field

Techcyte sells Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic and clinical pathology workflows by combining whole-slide imaging, deterministic convolutional neural network AI inference, intelligent worklists, synoptic reporting, and LIS/EHR integration. The platform is sold as modules (Fusion AP, Frozen Section, SureView Cervical Cytology, Parasitology, Bacteriology, Hematology, Organ Donation) plus the Sporecyte environmental mold testing brand, deployed to hospital systems, reference labs, and academic medical centers, with embedded AI delivered through the Zoetis Vetscan Imagyst OEM partnership.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1Techcyte Fusion
CategoryCore Platform / SaaS
Description

The unified anatomic and clinical pathology AI platform — a cloud-native, browser-based, SaaS-delivered workspace built on AWS with microservices and REST APIs that integrates whole-slide scanning, AI inference (Techcyte-built and 3rd-party via the Fusion Partner Program), intelligent worklist, ultra-fast slide viewer, synoptic reporting, LIS/EHR integration, and DICOMweb interoperability. Sells the Fusion AP, Fusion Frozen Section Suite, Fusion Parasitology Suite, Fusion Bacteriology Suite, Fusion Hematology Suite, Fusion Organ Donation Suite, and SureView Cervical Cytology System under one platform.

2Fusion AP
CategoryAnatomic Pathology Software Module
Description

Fusion Anatomic Pathology module supporting surgical pathology, cytology, dermatopathology, frozen section, breast, prostate, GI, non-GYN cytology, and renal workflows. Provides an ultra-fast multi-monitor slide viewer (up to 6 co-registered images), intelligent worklist with case routing/prioritization, in-app messaging, synoptic reporting, and integrated 3rd-party AI through the Fusion Partner Program (Aiforia, Aiosyn, Mindpeak, Modella AI, Deep Bio, Aira Matrix, BIOBASE, Voicebrook, Dolbey). For research use only in the US; CE-IVDR marked in the EU.

3Fusion Frozen Section Suite
CategoryAnatomic Pathology Software Module
Description

Digital workflow for frozen section labs that integrates Grundium Ocus 40 and Pramana Spectral-M scanners to digitize frozen section slides, route cases to pathologists, enable remote consultation, and deliver real-time intra-operative results to surgeons in the OR via a dedicated OR view. For research use only and not for diagnostic use in the US.

4Techcyte SureView Cervical Cytology System
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-01
Description

Techcyte integrated Aira Matrix AI into the Fusion AP digital pathology platform for prostate pathology AI; demonstrated in Episode 26 of Pioneers in Digital Pathology webinar series (April 2026).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-01
Description

Added to Techcyte Fusion Partner Program in March 2026, integrating voice-enabled workflow capabilities into the Techcyte Fusion digital pathology platform — enables pathologists to navigate cases, complete CAP reporting, and execute operational tasks via voice commands.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

Biobase and Techcyte partnered to advance digital pathology and unlock the full potential of clinical data. Biobase is a Fusion Partner Program member.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-01
Description

Research collaboration announced August 2025 with Modella AI's state-of-the-art agentic and generative AI-powered diagnostic pathology platform integrated into Techcyte Fusion.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-01
Description

Joined Techcyte Fusion Partner Program in August 2025 to integrate AI-powered prostate diagnostics and frozen section capabilities into the Fusion platform.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-07-01
Description

Germany-based Mindpeak partnered with Techcyte in July 2025 to integrate Mindpeak's explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics. Joined Techcyte Fusion Partner Program.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-01
Description

Strategic collaboration announced March 2025 to advance AI-powered digital pathology. Aiforia's AI models are integrated into the Fusion Partner Program for anatomic pathology workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-01
Description

Collaboration announced March 2025 to integrate AI-powered slide QC and mitotic counting into the Fusion digital pathology platform. Part of a three-way Techcyte/Pramana/Aiosyn Edge AI collaboration also announced in March 2025.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-01
Description

Three-way collaboration with Techcyte, Pramana, and Aiosyn announced March 2025 to advance digital pathology workflow with edge AI technology. Pramana Spectral-M Pro/HT2/HT4 scanners are supported across Techcyte's product lines.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic collaboration announced January 2024 to create an open, standards-based, AI-enabled comprehensive digital pathology platform (Fusion AP). Co-developed and validated the Fusion Bacteriology Suite (Gram stain). Mayo Clinic is also an investor (participated in $15M raise in 2026) and provides access to Safe Harbor dataset of 17M+ de-identified slides.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Strategic collaboration announced January/February 2024 with BD granted worldwide distribution of the AI-Based Digital Cervical Cytology System (Techcyte SureView). Collaboration addresses global shortage of skilled cytotechnologists.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

CompuMed integrated Techcyte Digital Pathology Platform to enhance digital manual review of available livers and kidneys for organ transplant availability (October 2023).

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Early collaborator and customer. Strategic partnership and investment established in 2018. Co-developed AI-based solutions for trichrome, modified acid fast, and wet mount iodine parasitology tests. Deployed world's first AI-augmented ova and parasite detection tool in 2019. Released fecal wet mount iodine solution with ARUP in 2025.

14Ketterthill (Luxembourg)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Strategic partnership established in 2018 — Techcyte partner for the BV Gram stain solution and clinical pathology in Luxembourg.

techcyte.com
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

Exclusive veterinary partner producing Vetscan Imagyst — Techcyte AI is embedded across fecal O&P, FNA, blood smears, dermatology, urine sediment, AI Masses cytology, equine tests. Surpassed 2 million tests (2023) and 3 million digital scans (2024) across the platform. Led Techcyte's $21M Series E in 2021 and participated in the 2026 $15M raise. Zoetis is the world's largest producer of veterinary medicine.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Strategic partnership and investment from Motic (2017). Motic scanners (Motic EasyScan One/Pro/Infinity) are supported across Techcyte product lines.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

Techcyte began as a technology transfer from the University of Utah in 2013. Founders Ralph Yarro and Rick Smith licensed a white-paper on white blood cell classification from Dr. Mohamed Salama. New study (Feb 2023) demonstrated value of AI in organ transplantation; donated to U of U Transplant Buddy Fund (May 2022).

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cloud-based digital pathology platform combining whole-slide image management with AI applications for biopharma, reference labs, and academic centers. Highly comparable to Techcyte Fusion in target customer, SaaS delivery model, and use of third-party AI integrations.

TypeDirect peer
Description

AI-powered pathology platform offering diagnostic AI for pharma services, clinical research, and diagnostic applications including oncology and IBD. Overlaps directly with Techcyte Fusion AP and SureView in anatomic/clinical pathology AI and uses similar deep-learning approaches on whole-slide images.

TypeDirect peer
Description

AI-native digital pathology company focused on cancer detection across prostate, breast, and other tumor types with FDA-cleared prostate AI. Directly comparable in AI capability type (CNN-based tumor detection on whole-slide images), target customer (academic medical centers, reference labs), and pathology category.

TypeDirect peer
Description

AI platform for cancer diagnostics deployed in clinical pathology workflows for breast, prostate, and GI biopsies with CE-marked and Galen platform. Closely comparable to Techcyte SureView and Fusion AP in use case, target lab customer, and clinical-grade AI deployment.

TypeDirect peer
Description

Cloud-based AI image analysis platform for pathology and other life-science imaging with a deep-learning model development environment. Both a Fusion Partner Program member and direct peer in AP AI workflows serving academic medical centers and pharma.

TypeDirect peer
Description

Provider of HALO digital pathology image analysis software and AI/deep-learning toolkits used by pharma, CROs, and research pathology labs. Comparable to Techcyte Fusion in AP use cases, image-management stack, and AI module ecosystem.

TypeDirect peer
Description

AI-driven digital pathology software (Phenoptics, Oncotopix) for research and clinical workflows including cancer diagnostics. Comparable AP AI offering and target customers in pharma and clinical research.

TypeBroad incumbent
Description

Owner of IntelliSite Pathology Solution — an enterprise digital pathology platform with whole-slide scanners, image management, and AI ecosystem including iSyntax. Broader portfolio player with deeper hospital relationships than Techcyte; same AP end-user segment and DICOM/PACS-style integration.

TypeBroad incumbent
Description

Operates the uPath digital pathology platform combined with VENTANA slide scanners and staining systems and a broad companion-diagnostic AI portfolio. Direct overlap with Techcyte Fusion AP, SureView, and the partner-AI model; major incumbent competitor and potential partner/customer.

TypeBroad incumbent
Description

Provider of Aperio digital pathology scanners and software widely deployed across hospital systems and academic centers. Comparable AP/CP use cases and whole-slide image formats (SVS); entrenched incumbent in the same customer base as Techcyte.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration29 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Techcyte

Digital Pathology AI Softwaretechcyte.com

Techcyte builds Fusion, a cloud-based AI platform that unifies anatomic and clinical pathology workflows using deep learning on whole-slide images. It serves human clinical labs, veterinary clinics (via Zoetis), environmental testing labs, and food safety markets.

What Techcyte does

Techcyte is a digital pathology AI company founded in 2013 as a technology transfer from the University of Utah and headquartered in Orem, Utah. The company builds Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic pathology (AP) and clinical pathology (CP) workflows into a single workspace, addressing a market historically served by fragmented, single-purpose tools. Techcyte's core AI is built on proprietary deterministic convolutional neural networks trained to detect, classify, and count diagnostic objects (parasites, blood cells, bacteria, cervical cells, and pathology structures) on whole-slide microscopy images, validated with quantified accuracy metrics ranging from 95% to 98.9% in published studies. The platform is DICOM-native, supports all major WSI scanner formats, uses a microservices architecture on AWS, and integrates with LIS/EHR/PACS systems via HL7, FHIR, and DICOMweb standards.

The company operates across four verticals: human clinical pathology (parasitology, bacteriology, hematology, cervical cytology via SureView), veterinary diagnostics (embedded as the AI engine for Zoetis's Vetscan Imagyst platform), environmental testing (Sporecyte brand for mold and air quality), and food safety (Stericyte brand launched 2025). Revenue is generated through multi-year SaaS subscriptions, OEM/embedded licensing royalties (notably from Zoetis, where Techcyte AI powered 3M+ scans by 2024), professional services, and scanner distribution partnerships. Distribution combines direct enterprise sales, exclusive OEM partnerships (Zoetis for veterinary, BD for cervical cytology), and an ESP (Expert Solution Provider) international channel program. The company has raised approximately $36M+ across seed rounds, a 2021 Series E led by Zoetis, and a 2026 capital raise led by Van Tuyl Companies, with the veterinary segment already profitable and human/environmental segments targeting profitability by 2027.

Techcyte firmographics

Firmographics
Name
Techcyte
Legal name
Techcyte, Inc.
Website
https://techcyte.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Techcyte builds Fusion, a cloud-based AI platform that unifies anatomic and clinical pathology workflows using deep learning on whole-slide images. It serves human clinical labs, veterinary clinics (via Zoetis), environmental testing labs, and food safety markets.
Ownership category
akta.pro rank

Techcyte industry classification

Industry
Product category
Digital Pathology AI Software
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Digital pathology
  • Clinical pathology AI
  • Anatomic pathology
  • Cytology diagnostics
  • Laboratory diagnostics

Where Techcyte is headquartered

Location

Headquarters

HQ city
Orem
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Techcyte business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Subscription/SaaS: Recurring subscription-based revenue from hosted SaaS access to Techcyte Fusion and related AI suites. Customers must sign subscription agreements to use the platform (per ESP portal terms). Includes ESP (Expert Solution Provider) international distribution tier.
  2. Scanner distribution / hardware resale: Techcyte acts as a trusted distributor of top whole-slide scanners (Hamamatsu, 3DHistech, Pramana, Motic, Grundium, MetaSystems), generating revenue from hardware sales or referral arrangements to support its platform deployments.
  3. OEM/embedded licensing (Zoetis Vetscan Imagyst): Techcyte AI algorithms are embedded within Zoetis's Vetscan Imagyst platform — generating royalty/licensing revenue per test analyzed. Surpassed 3 million digital scans across Zoetis platform (2024) and over 2 million scans by 2023.
  4. Professional services / implementation: Implementation, training, onboarding, scanner consultation, and ongoing support services delivered alongside platform deployments; supported by in-app training and dedicated account management.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractCustom enterprise subscription

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Techcyte product offering

Product offering

Core offering

Techcyte sells Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic and clinical pathology workflows by combining whole-slide imaging, deterministic convolutional neural network AI inference, intelligent worklists, synoptic reporting, and LIS/EHR integration. The platform is sold as modules (Fusion AP, Frozen Section, SureView Cervical Cytology, Parasitology, Bacteriology, Hematology, Organ Donation) plus the Sporecyte environmental mold testing brand, deployed to hospital systems, reference labs, and academic medical centers, with embedded AI delivered through the Zoetis Vetscan Imagyst OEM partnership.

Differentiator

Problem solved

Functional benefit

Brands

  • Vetcyte: AI-powered digital diagnostics platform for the veterinary industry, originally split out as a separate brand in 2016; powers VETSCAN IMAGYST in partnership with Zoetis.
  • Sporecyte
  • Stericyte
  • Techcyte Fusion
  • Techcyte SureView

Products and services

  • Techcyte Fusion The unified anatomic and clinical pathology AI platform — a cloud-native, browser-based, SaaS-delivered workspace built on AWS with microservices and REST APIs that integrates whole-slide scanning, AI inference (Techcyte-built and 3rd-party via the Fusion Partner Program), intelligent worklist, ultra-fast slide viewer, synoptic reporting, LIS/EHR integration, and DICOMweb interoperability. Sells the Fusion AP, Fusion Frozen Section Suite, Fusion Parasitology Suite, Fusion Bacteriology Suite, Fusion Hematology Suite, Fusion Organ Donation Suite, and SureView Cervical Cytology System under one platform.
  • Fusion AP Fusion Anatomic Pathology module supporting surgical pathology, cytology, dermatopathology, frozen section, breast, prostate, GI, non-GYN cytology, and renal workflows. Provides an ultra-fast multi-monitor slide viewer (up to 6 co-registered images), intelligent worklist with case routing/prioritization, in-app messaging, synoptic reporting, and integrated 3rd-party AI through the Fusion Partner Program (Aiforia, Aiosyn, Mindpeak, Modella AI, Deep Bio, Aira Matrix, BIOBASE, Voicebrook, Dolbey). For research use only in the US; CE-IVDR marked in the EU.
  • Fusion Frozen Section Suite Digital workflow for frozen section labs that integrates Grundium Ocus 40 and Pramana Spectral-M scanners to digitize frozen section slides, route cases to pathologists, enable remote consultation, and deliver real-time intra-operative results to surgeons in the OR via a dedicated OR view. For research use only and not for diagnostic use in the US.
  • Techcyte SureView Cervical Cytology System

Companies that use Techcyte

Customer profile

Named customers12 records

Segments6 records

Ideal customer profiles5 records

Techcyte technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration29 records

AI capability10 records

Feature7 records

Techcyte partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core, flagship and minor.

  • Aira MatrixcoreTechnology or Integration · 1 May 2026Techcyte integrated Aira Matrix AI into the Fusion AP digital pathology platform for prostate pathology AI; demonstrated in Episode 26 of Pioneers in Digital Pathology webinar series (April 2026).
  • VoicebrookcoreTechnology or Integration · 1 March 2026Added to Techcyte Fusion Partner Program in March 2026, integrating voice-enabled workflow capabilities into the Techcyte Fusion digital pathology platform — enables pathologists to navigate cases, complete CAP reporting, and execute operational tasks via voice commands.
  • BiobasecoreTechnology or Integration · 1 January 2026Biobase and Techcyte partnered to advance digital pathology and unlock the full potential of clinical data. Biobase is a Fusion Partner Program member.
  • Modella AIcoreTechnology or Integration · 1 August 2025Research collaboration announced August 2025 with Modella AI's state-of-the-art agentic and generative AI-powered diagnostic pathology platform integrated into Techcyte Fusion.
  • Deep BiocoreTechnology or Integration · 1 August 2025Joined Techcyte Fusion Partner Program in August 2025 to integrate AI-powered prostate diagnostics and frozen section capabilities into the Fusion platform.
  • Mindpeak GmbHcoreTechnology or Integration · 1 July 2025Germany-based Mindpeak partnered with Techcyte in July 2025 to integrate Mindpeak's explainable AI tools into Techcyte's cloud-based Fusion platform, aiming to improve accuracy and transparency in pathology diagnostics. Joined Techcyte Fusion Partner Program.
  • AiforiacoreTechnology or Integration · 1 March 2025Strategic collaboration announced March 2025 to advance AI-powered digital pathology. Aiforia's AI models are integrated into the Fusion Partner Program for anatomic pathology workflows.
  • AiosyncoreTechnology or Integration · 1 March 2025Collaboration announced March 2025 to integrate AI-powered slide QC and mitotic counting into the Fusion digital pathology platform. Part of a three-way Techcyte/Pramana/Aiosyn Edge AI collaboration also announced in March 2025.
  • PramanacoreTechnology or Integration · 1 March 2025Three-way collaboration with Techcyte, Pramana, and Aiosyn announced March 2025 to advance digital pathology workflow with edge AI technology. Pramana Spectral-M Pro/HT2/HT4 scanners are supported across Techcyte's product lines.
  • Mayo Clinic PlatformflagshipStrategic or Co-development Partner · 1 January 2024Strategic collaboration announced January 2024 to create an open, standards-based, AI-enabled comprehensive digital pathology platform (Fusion AP). Co-developed and validated the Fusion Bacteriology Suite (Gram stain). Mayo Clinic is also an investor (participated in $15M raise in 2026) and provides access to Safe Harbor dataset of 17M+ de-identified slides.
  • BD (Becton, Dickinson and Company)flagshipChannel Partner/ Reseller/ Distributor · 1 January 2024Strategic collaboration announced January/February 2024 with BD granted worldwide distribution of the AI-Based Digital Cervical Cytology System (Techcyte SureView). Collaboration addresses global shortage of skilled cytotechnologists.
  • CompuMedcoreStrategic or Co-development Partner · 1 October 2023CompuMed integrated Techcyte Digital Pathology Platform to enhance digital manual review of available livers and kidneys for organ transplant availability (October 2023).
  • ARUP LaboratoriesflagshipStrategic or Co-development Partner · 1 January 2018Early collaborator and customer. Strategic partnership and investment established in 2018. Co-developed AI-based solutions for trichrome, modified acid fast, and wet mount iodine parasitology tests. Deployed world's first AI-augmented ova and parasite detection tool in 2019. Released fecal wet mount iodine solution with ARUP in 2025.
  • Ketterthill (Luxembourg)minorStrategic or Co-development Partner · 1 January 2018Strategic partnership established in 2018 — Techcyte partner for the BV Gram stain solution and clinical pathology in Luxembourg.
  • ZoetisflagshipOEM/ Whitelabel/ Licensing Partner · 1 January 2017Exclusive veterinary partner producing Vetscan Imagyst — Techcyte AI is embedded across fecal O&P, FNA, blood smears, dermatology, urine sediment, AI Masses cytology, equine tests. Surpassed 2 million tests (2023) and 3 million digital scans (2024) across the platform. Led Techcyte's $21M Series E in 2021 and participated in the 2026 $15M raise. Zoetis is the world's largest producer of veterinary medicine.
  • MoticcoreStrategic or Co-development Partner · 1 January 2017Strategic partnership and investment from Motic (2017). Motic scanners (Motic EasyScan One/Pro/Infinity) are supported across Techcyte product lines.
  • University of UtahflagshipStrategic or Co-development Partner · 1 January 2013Techcyte began as a technology transfer from the University of Utah in 2013. Founders Ralph Yarro and Rick Smith licensed a white-paper on white blood cell classification from Dr. Mohamed Salama. New study (Feb 2023) demonstrated value of AI in organ transplantation; donated to U of U Transplant Buddy Fund (May 2022).

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

Techcyte competitors and assessment

Company assessment

Direct peers

  • Proscia: Cloud-based digital pathology platform combining whole-slide image management with AI applications for biopharma, reference labs, and academic centers. Highly comparable to Techcyte Fusion in target customer, SaaS delivery model, and use of third-party AI integrations.
  • PathAI: AI-powered pathology platform offering diagnostic AI for pharma services, clinical research, and diagnostic applications including oncology and IBD. Overlaps directly with Techcyte Fusion AP and SureView in anatomic/clinical pathology AI and uses similar deep-learning approaches on whole-slide images.
  • Paige.AI: AI-native digital pathology company focused on cancer detection across prostate, breast, and other tumor types with FDA-cleared prostate AI. Directly comparable in AI capability type (CNN-based tumor detection on whole-slide images), target customer (academic medical centers, reference labs), and pathology category.
  • Ibex Medical Analytics: AI platform for cancer diagnostics deployed in clinical pathology workflows for breast, prostate, and GI biopsies with CE-marked and Galen platform. Closely comparable to Techcyte SureView and Fusion AP in use case, target lab customer, and clinical-grade AI deployment.
  • Aiforia: Cloud-based AI image analysis platform for pathology and other life-science imaging with a deep-learning model development environment. Both a Fusion Partner Program member and direct peer in AP AI workflows serving academic medical centers and pharma.
  • Indica Labs: Provider of HALO digital pathology image analysis software and AI/deep-learning toolkits used by pharma, CROs, and research pathology labs. Comparable to Techcyte Fusion in AP use cases, image-management stack, and AI module ecosystem.
  • Visiopharm: AI-driven digital pathology software (Phenoptics, Oncotopix) for research and clinical workflows including cancer diagnostics. Comparable AP AI offering and target customers in pharma and clinical research.

Broad incumbents

  • Philips (Philips Digital Pathology): Owner of IntelliSite Pathology Solution — an enterprise digital pathology platform with whole-slide scanners, image management, and AI ecosystem including iSyntax. Broader portfolio player with deeper hospital relationships than Techcyte; same AP end-user segment and DICOM/PACS-style integration.
  • Roche (VENTANA / Roche Digital Pathology): Operates the uPath digital pathology platform combined with VENTANA slide scanners and staining systems and a broad companion-diagnostic AI portfolio. Direct overlap with Techcyte Fusion AP, SureView, and the partner-AI model; major incumbent competitor and potential partner/customer.
  • Leica Biosystems (Danaher): Provider of Aperio digital pathology scanners and software widely deployed across hospital systems and academic centers. Comparable AP/CP use cases and whole-slide image formats (SVS); entrenched incumbent in the same customer base as Techcyte.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Techcyte social profiles

Digital presence

Techcyte compliance and trust

Trust signal

Compliance8 records

Techcyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Techcyte leadership team

Management profile

Number of profiles

Profiles17 records

Techcyte subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Techcyte funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Techcyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Techcyte

What does Techcyte do?

Techcyte sells Techcyte Fusion, a cloud-native, browser-based SaaS platform that unifies anatomic and clinical pathology workflows by combining whole-slide imaging, deterministic convolutional neural network AI inference, intelligent worklists, synoptic reporting, and LIS/EHR integration. The platform is sold as modules (Fusion AP, Frozen Section, SureView Cervical Cytology, Parasitology, Bacteriology, Hematology, Organ Donation) plus the Sporecyte environmental mold testing brand, deployed to hospital systems, reference labs, and academic medical centers, with embedded AI delivered through the Zoetis Vetscan Imagyst OEM partnership.

Is Techcyte a public or private company?

Techcyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was Techcyte founded?

Techcyte was founded in 2013. It employs 101 to 250 people.

Where is Techcyte based?

Techcyte is headquartered in Orem, United States, in the North America region.

How does Techcyte make money?

Four revenue lines are on record. Subscription/SaaS are the primary driver. The others are scanner distribution / hardware resale, OEM/embedded licensing (Zoetis Vetscan Imagyst) and professional services / implementation.

Who are Techcyte's main competitors?

Direct peers on record are Proscia, PathAI, Paige.AI, Ibex Medical Analytics, Aiforia, Indica Labs and Visiopharm. Broad incumbents are Philips (Philips Digital Pathology), Roche (VENTANA / Roche Digital Pathology) and Leica Biosystems (Danaher).

Does Techcyte have an API?

Yes. Techcyte Fusion is built using a microservices architecture and exposes REST APIs (described as "RESTless APIs") for platform integration. A complete, documented API enables integration with laboratory information systems (LIS), electronic health records (EHR), grossing stations, and radiology systems. The platform also supports DICOMweb access to whole slide image archives (query/fetch on-demand) and integrates with the Techcyte Connect Uploader for ingesting DICOM ZIP outputs from whole slide scanners. Fusion is deployed on AWS for global scalability, uses the OAuth framework with Auth0 for role-based SSO, and is DICOM-first by design. The Fusion Partner Program also exposes a unified third-party AI API for integrating partner algorithms into Fusion Anatomic Pathology workflows.

What industry is Techcyte in?

Techcyte's product category is Digital Pathology AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireTyrolpath Connects Cytology and Histology Workflows with Techcyte Fusion® APTyrolpath, an Austrian pathology lab, began clinical sign-out of dermatopathology cases in Techcyte Fusion AP in September. The lab also uses SureView for cervical cytology and is running a validation study to extend Fusion AP across more anatomic pathology this fall.EIN PresswireTyrolpath Connects Cytology and Histology Workflows with Techcyte Fusion® APTyrolpath added Techcyte Fusion AP for digital histology review in 2025, after implementing SureView for cervical cytology. The lab began clinical sign-out of dermatopathology cases in Fusion AP in September and is running a validation study to extend it across more anatomic pathology. Techcyte aims to support digital workflows across microbiology and other areas.EIN PresswireAtlantic Pathology Adds Techcyte SureView® to Cervical Cytology Quality Control WorkflowAtlantic Pathology in Puerto Rico went live with Techcyte SureView for AI-assisted quality control of ThinPrep Pap tests. The system digitizes slides on a Hamamatsu S360 scanner and integrates with the lab's LIS. Atlantic Pathology is also implementing Techcyte Fusion AP as part of a broader digital pathology strategy.EIN PresswireAtlantic Pathology Adds Techcyte SureView® to Cervical Cytology Quality Control WorkflowAtlantic Pathology, a Puerto Rico-based pathology lab, added Techcyte SureView to its cervical cytology quality control workflow. The system uses whole slide imaging and AI-assisted analysis, and the lab is also implementing Techcyte Fusion AP as part of a broader digital pathology strategy.EIN PresswireTechcyte and EVIDENT Expand Partnership with Flexible Business Models for End-to-End Digital PathologyTechcyte and Evident expanded their partnership to offer flexible business models for end-to-end digital pathology, combining Evident's Pramana scanners with Techcyte's Fusion platform. The collaboration extends digital pathology beyond histology to cytology, hematology, microbiology, and parasitology, with customers able to choose acquisition options.Business & FinancialTechcyte And EVIDENT Expand Partnership With Flexible Business Models For End-To-End Digital PathologyTechcyte and Evident expanded their partnership to offer flexible business models for end-to-end digital pathology, combining Evident's Pramana scanners with Techcyte's Fusion platform. The collaboration extends beyond histology to cytology, hematology, microbiology, and parasitology, with modular architecture and quality-assured imaging. The companies will showcase the partnership at Pathology Visions 2026 in San Diego.EIN PresswireTechcyte, Aignostics launch AI-guided NGS macrodissection workflowTechcyte and Aignostics launched an AI-guided macrodissection workflow for next-generation sequencing on Techcyte Fusion AP, using Aignostics' HETA Tumor Cellularity. The workflow helps pathologists identify tumor-rich regions and set scraping boundaries, aiming to reduce failed or repeated molecular tests. The announcement came ahead of Pathology Visions 2026 in San Diego.EIN PresswirePictor Labs' ClearStain™ Virtual H&E Now Available in Techcyte Fusion® AP for Molecular Tissue SelectionPictor Labs' ClearStain virtual H&E is now integrated into Techcyte Fusion AP, allowing pathologists to annotate unstained tissue sections for molecular extraction. The integration uses a proprietary algorithm to generate a virtual H&E from a brightfield scan, preserving the physical section for downstream work. It is available separately via Cloud or On-Prem deployment.EIN PresswireNGS macrodissection workflow available from Techcyte and AignosticsTechcyte and Aignostics announced a collaboration to integrate Aignostics' HETA Tumor Cellularity AI analysis into Techcyte's Fusion AP digital pathology workflow. The workflow guides pathologists in selecting tumor-rich regions for macrodissection, aiming to reduce sequencing failures due to insufficient tumor content. The workflow will be showcased at Pathology Visions 2026 in San Diego.EIN PresswireTechcyte works with Aignostics to Preview Tissue Microarray Workflow Connecting Fusion AP to TMA Grand Master by EprediaTechcyte is developing an integration with Aignostics and Epredia to connect its Fusion AP platform with the 3DHISTECH TMA Grand Master, enabling automated coring of confirmed regions of interest from digital slides. The first phase, moving DICOM images and ROI annotations, will be presented at Pathology Visions 2026.